Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection

A technology of Acinetobacter baumannii and carbapenems, which is applied in the field of medicine and can solve problems such as lack of antibiotic compositions

Inactive Publication Date: 2020-09-15
GUANGZHOU CENTURY CLINICAL RES CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For carbapenem-resistant Acinetobacter baumannii infection, there is currently a lack of effective antibiotic combinations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection
  • Composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection
  • Composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: In vitro bacteriostatic effect of sulbactam and low proportion of ceftazidime on drug-resistant Acinetobacter baumannii

[0054] Strains: 157 clinical isolates of Acinetobacter baumannii resistant to carbapenem antibiotics were selected and named CR-Ab. The selection criteria are: clinically isolated Acinetobacter baumannii, the drug susceptibility test is carried out with imipenem and meropenem, which are commonly used carbapenems, according to the CLSI paper method. One or two drug resistances in Nanzhong were selected as inclusion criteria. Resistance refers to the MIC of imipenem or / and meropenem ≥ 8 μg / ml according to the criteria of Table 2B-2 of CLSI-M100 27th.

[0055] Drugs: take sulbactam and ceftazidime, and prepare the compositions in different proportions. The method is to fix the amount of sulbactam and gradually reduce the amount of ceftazidime to obtain the weight ratios of sulbactam and ceftazidime of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 ...

Embodiment 2

[0061] Example 2: In vitro long-term bactericidal effect of sulbactam in combination with low-proportion ceftazidime on drug-resistant Acinetobacter baumannii

[0062] Strain: carbapenem-resistant Acinetobacter baumannii CR-Ab in Example 1.

[0063] Medicines: four sulbactam-ceftazidime compositions with ratios of 1:1, 1:0.8, 1:0.4 and 1:0.2 prepared in Example 1, respectively.

[0064] Methods: Five CR-Ab strains were selected, and each composition was used for drug susceptibility tests to obtain their respective MIC values. Then the strain was cultured with MH broth to obtain a concentration of 10 6 CFU / mL of bacteria was used as the inoculum. Take the bacterial inoculation mother liquor respectively, add each medicine respectively, make the final concentration of the medicine (calculated by the concentration of sulbactam) respectively 0 (negative control), 0.25MIC, 1MIC, 2MIC, 4MIC, 8MIC, 16MIC, respectively, at 0, Samples were taken at each time point of 2, 4, 6, 8, 12,...

Embodiment 3

[0076] Example 3: Protective effect of sulbactam in combination with low proportion of ceftazidime on pneumonia model animals infected with drug-resistant Acinetobacter baumannii

[0077] Drug: each composition of sulbactam and ceftazidime used in Example 1 in the ratio of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 and 1:0.1, with water for injection It is formulated into a drug solution; the commercially available meropenem is formulated into a drug solution with water for injection; the commercially available meropenem, plus sulbactam, is formulated into a 1:1 drug solution of meropenem and sulbactam with water for injection.

[0078] Strain: Use CR-Ab strain, cultivated to a concentration of 10 8 CFU / mL bacterial solution.

[0079] Animals: Male C57BL / 6 mice, randomly divided into normal control group, model control group, meropenem group, meropenem-sulbactam 1:1 group, sulbactam-ceftazidime 1:1 group, and sulbactam-ceftazidime 1:0.9 group , Sulbactam-ceftazidime 1:0.8 group,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection. The inventor studies and finds that a combination of sulbactam and ceftazidime ina specific ratio has an excellent treatment effect on CR-Ab infection, and the treatment effect of the combination is even better than that of a composition of carbapenem and sulbactam.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a method and a composition for treating the infection caused by Acinetobacter baumannii, particularly the infection caused by carbapenem-resistant Acinetobacter baumannii. Background technique [0002] Acinetobacter baumannii is a non-fermenting Gram-negative bacteria and is an important pathogenic bacteria. Acinetobacter baumannii is increasingly recognized as an important cause of serious infections. Clinically, severe infections of respiratory, blood, abdominal cavity, central nervous system, urinary and skin and soft tissue systems are closely related to Acinetobacter baumannii. [0003] Li Xiangxin et al. (Chinese Journal of Antibiotics, 2007, 32(12): 762-764) retrospectively investigated the clinical distribution of Acinetobacter baumannii isolated from clinical practice from January 2002 to December 2006, and found that 865 The strains of Acinetobacter baumannii were mainly deriv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/43A61K31/546A61P31/04
CPCA61K31/43A61K31/546A61P31/04A61K2300/00A61P31/00Y02A50/30
Inventor 不公告发明人
Owner GUANGZHOU CENTURY CLINICAL RES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com